Stock ENTX ENTERA BIO LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Entera Bio Ltd.

Equities

ENTX

IL0011429839

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
2.07 USD -6.76% Intraday chart for Entera Bio Ltd. -6.76% +245.00%
Apr. 08 Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research CI
Mar. 26 Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months CI

Evolution of the average Target Price on Entera Bio Ltd.

Price target over the last 5 years

History of analyst recommendation changes

8c38e56d2f34b4f92c5adae37.uEgVWVm53YvjZ4xZr5sdBk41GRSMlCb5A83gNj93nfM.wicmHmHVl8WOX9kc7dZOPhZZV3u_7FGaMqarZn0S74XeGiEfA-yv1Ikp7w~9756738ebf4fe89aa645390b72554257

Analyst Recommendations on Entera Bio Ltd.

HC Wainwright Initiates Entera Bio at Buy With $10 Price Target MT
B. Riley Securities Trims Entera Bio's Price Target to $5 from $6 to Reflect Delayed Clinical/Regulatory Path, Keeps Buy Rating MT
Maxim Group Adjusts Entera Bio Price Target to $6 From $10, Maintains Buy Rating MT
B. Riley Lowers Entera Bio's Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
ENTERA BIO : B. Riley Lowers Entera Bio's PT to $11 from $14 Following Results from Phase II Study of EB613 Osteoporosis Treatment, Keeps Buy Rating MT
ENTERA BIO : B. Riley Raises Entera Bio's PT to $14 from $9 After Encouraging Clinical Results of EB613 Study, Keeps Buy Rating MT
ENTERA BIO : B. Riley Starts Entera Bio at Buy with $9 PT, Notes Lead Program's Potential to be First Oral Osteoanabolic Product to Treat Osteoporosis MT
ENTERA BIO : Aegis Capital Initiates Entera Bio at Buy Rating With $12 Price Target MT
ENTERA BIO : Maxim Adjusts Price Target on Entera Bio to $10 From $5, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.07 USD
Average target price
10 USD
Spread / Average Target
+383.09%
High Price Target
10 USD
Spread / Highest target
+383.09%
Low Price Target
10 USD
Spread / Lowest Target
+383.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Entera Bio Ltd.

HC Wainwright
B. Riley
Maxim
Aegis Capital

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ENTX Stock
  4. Consensus Entera Bio Ltd.